AgingResearch.NewsJoin free

Medicenna

CompanyCanada

Medicenna develops one asset, in phase 2 (MDNA11 in advanced and metastatic gastrointestinal cancer). Mostly protein or enzyme acting on IL2RB and IL2RG; based in Canada.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • MDNA11

    Engineered IL-2 superkine designed to selectively activate effector T and NK cells

    Phase 2, Protein or enzyme, IL2RB, IL2RG, advanced and metastatic gastrointestinal cancer, endometrial cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Similar companies6

Intelligence